19271-19-3

Basic information

• Product Name: Methyl6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate
• Synonyms: Methyl6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate;6-Fluoro-1,4-dihydro-4-oxo-2-quinolinecarboxylic acid methyl ester;6-Fluoro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid Methyl ester
• CAS NO: 19271-19-3
• Molecular Formula: C₁₁H₈FNO₃
• Molecular Weight: 221
• Mol File: 19271-19-3.mol

Chemical Properties

• Boiling Point: 336℃
• Flash Point: 157℃
• Appearance: /
• Density: 1.366
• Vapor Pressure: 0.000119mmHg at 25°C
• Refractive Index: 1.561
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Methyl6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate(19271-19-3)
• EPA Substance Registry System: Methyl6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate(19271-19-3)

Safety Data

• Hazardous Substances Data: 19271-19-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate is used as an active pharmaceutical ingredient for its antibacterial and antimicrobial properties. It is employed in the synthesis of various pharmaceutical drugs to combat bacterial infections.
Used in Drug Development:
Methyl 6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate is used as a building block in the development of new drugs. Its potent biological activity and ability to inhibit the growth of various bacterial strains make it a promising candidate for the creation of novel antibiotics and antimicrobial agents.
Used in Research and Development:
Methyl 6-fluoro-4-oxo-1,4-dihydroquinoline-2-carboxylate is used in research and development for its potential therapeutic applications. It has shown promising results in inhibiting the growth of various bacterial strains, and further studies are being conducted to explore its potential in the treatment of bacterial infections.

InChI:InChI=1/C11H8FNO3/c1-16-11(15)9-5-10(14)7-4-6(12)2-3-8(7)13-9/h2-5H,1H3,(H,13,14)

Upstream product

• 20866-71-1 (p-fluoroanilino)-fumaric acid, dimethyl ester 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 301823-61-0 4-chloro-6-fluoro-quinoline-2-carboxylic acid methyl ester 
• 530077-39-5 methyl 1-{[(benzoylamino)carbonyl]amino}-6-fluoro-4-oxo-1,4-dihydro-2-quinolinecarboxylate 
• 530077-29-3 methyl 6-fluoro-1-[({[(4-methylphenyl) sulfonyl]amino}carbonyl)amino]-4-oxo-1,4-dihydro-2-quinolinecarboxylate 
• 1444310-03-5 6-fluoro-1,4-dihydro-N′-(3-hydroxy-2-cyclohexenylidene)-4-oxoquinoline-2-carbohydrazide 
• 301823-80-3 4-ethoxy-6-fluoro-quinoline-2-carboxylic acid 2,4,6-trichloro-phenyl ester 
• 353290-51-4 1-(2-benzyloxy-ethyl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid ethyl ester 
• 353290-46-7 1-(2-benzyloxy-ethyl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid 

Relevant articles and documents

Quinolone analogues 12: Synthesis and tautomers of 2-substituted 4-quinolones and related compounds

The 4-quinolone-2-carboxylates 4a,b were converted into the 4-quinolone-2-carbohydrazides 5a,b, hydrazones 6,7,10, and related compounds 8,9,11. The 4-methoxyquinoline-2-carboxylate 12 was also transformed into the 4-methoxyquinoline-2-carbohydrazide 13, which was modified to the hydrazone 14 and related compound 15. The antimicrobial activities of compounds 6b and 14 are described together with the 4-oxo and 4-hydroxy tautomers of compounds 4-11 in deuteriodimethyl sulfoxide and deuteriotrifluoroacetic acid.

ACIDIC QUINOLINE DERIVATIVES AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF HYPERGLYCAEMIA-RELATED PATHOLOGIES

The invention relates to compounds of the general formula (I): in which RI, R2, X, (II) and A are as defined in Claim 1. These compounds can be used in the treatment of hyperglycaemia-related pathologies.

2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

Compounds of formula (I), where m, n, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Platelet adenosine diphosphate receptor antagonists

Compounds of the following formula (I): where a, b, R1, R2, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, met

Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents

The synthesis and in vivo activities of a series of substituted quinoline carboxyguanidines as a possible novel class of antidiabetic agents is described. (C) 2000 Elsevier Science Ltd. All rights reserved.